What is DNAtrix?
DNAtrix is a privately held biotech company specializing in innovative virus-driven immunotherapies designed to combat cancer. Their core technology utilizes an engineered common cold virus, modified to selectively target and eliminate cancer cells while sparing healthy tissue. This approach positions DNAtrix at the forefront of oncolytic virotherapy. The company's pipeline includes DNX-2401, a promising candidate slated for a global pivotal Phase 3 study in recurrent glioblastoma, and DNX-2440, currently in Phase 1 trials for metastatic cancers. The company's commitment to addressing challenging oncological indications is supported by substantial backing.
How much funding has DNAtrix raised?
DNAtrix has raised a total of $41.9M across 12 funding rounds:
Other Financing Round
$479K
Other Financing Round
$170K
Other Financing Round
$4.5M
Private Equity
$885K
Multiple Rounds
$2.5M
Grant
$10.8M
Series B
$20M
Grant
$2M
Debt
$350K
Other Financing Round (2008): $479K led by Mercury Fund
Other Financing Round (2010): $170K supported by Mercury Fund
Other Financing Round (2012): $4.5M featuring Mercury Fund
Private Equity (2012): $885K, investors not publicly disclosed
Other Financing Round (2013): $160K with participation from Mercury Fund
Other Financing Round (2013): $840K led by Mercury Fund
Series A (2013): $1.5M, investors not publicly disclosed
Grant (2014): $10.8M featuring Cancer Prevention & Research Institute of Texas
Series B (2014): $20M backed by Mercury Fund, Targeted Technology Fund, and Morningside Ventures
Grant (2016): $2M with participation from U.S. Food & Drug Administration
Debt (2020): $350K led by PPP
Key Investors in DNAtrix
Mercury Fund
Mercury Fund is an early-stage venture capital firm that invests in innovative technology companies. Their focus often includes software, IT, and other technology-driven sectors, providing crucial seed and early-stage capital to promising startups.
Targeted Technology Fund
Targeted Technology Fund is a venture capital firm specializing in early-stage investments in companies that advance groundbreaking or disruptive technologies to enhance medical practices and patient outcomes, with a focus on life sciences and medical devices.
Morningside Ventures
Morningside Ventures is a venture capital firm with a broad investment focus, often including life sciences and healthcare, aiming to support companies with significant growth potential and innovative technologies.
What's next for DNAtrix?
With the recent influx of major strategic investment, DNAtrix is poised to accelerate its clinical development programs, particularly the pivotal Phase 3 trial for DNX-2401. This enterprise-level financing will likely support expanded research and development efforts, potentially enabling further exploration of their adenovirus platform across a broader range of cancer types. The company's focus on obtaining regulatory designations, such as FDA Fast Track and Rare Pediatric Disease status for DNX-2401, signals a clear path toward potential commercialization and underscores the strategic importance of this latest capital infusion for future growth and market penetration.
See full DNAtrix company page
